Separation of circulating microRNAs using apheresis in patients with systemic lupus erythematosus
ABSTRACT: Examined the removal or reduction of circulating miRNAs with apheresis. The levels of expression of a large number of circulating miRNAs were measured in the plasma samples separated by the primary membranes from all 3 patients with systemic lupus erythematosus. This is the first report that circulating miRNAs in peripheral blood can be separated and possibly directly removed using membrane separation apheresis. Overall design: Collected blood and separated plasma samples from 3 patients with systemic lupus erythematosus who were undergoing plasmapheresis at our hospital. Peripheral blood was collected before and after it was passed through a primary membrane, centrifuged, and used to extract circulating miRNAs.
Project description:Study of high-density lipoproteins using 6 human plasma samples. The study sought to find small RNA signatures in systemic erythematosus lupus. Overall design: 6 different human plasma samples - 3 healthy controls and 3 systemic lupus erythematosus. RNA source for all samples is HDL-containing protein-lipid-RNA complex and RNA isolation kit used is miRNeasy (Qiagen). Starting material was total RNA.
Project description:Both multiple myeloma (MM) and systemic lupus erythematosus (SLE) are characterized with abnormal production of plasma cells. To explore the novel therapeutic target to plasma cells, we determined the gene expression profile in plasma cells by affymetrix microarrays. LPS could effectively in vitro induce the production of plasma cells. The splenocytes were separated from three C57BL/6 mice per group. B cells were sorted by B220 microbeads, and stimulated for 3 days in vitro by 10 ug/ml LPS. The transcripts in LPS-stimulated B cells were determined by Affymetrix Microarrays.
Project description:Gene expression profile studies have identified an interferon signature in whole blood or mononuclear cell samples from patients with systemic lupus erythematosus. This study was designed to determine whether specific lymphocyte and myeloid subsets freshly isolated from the blood of systemic lupus erythematosus patients demonstrated unique gene expression profiles compared to subsets isolated from healthy controls. Experiment Overall Design: The entire study included 67 samples. One CEL file was not available for SLE13_CD4
Project description:Gene expression profile studies have identified an interferon signature in whole blood or mononuclear cell samples from patients with systemic lupus erythematosus. This study was designed to determine whether specific lymphocyte and myeloid subsets freshly isolated from the blood of systemic lupus erythematosus patients demonstrated unique gene expression profiles compared to subsets isolated from healthy controls. Keywords: patient compared to control Overall design: The entire study included 67 samples. One CEL file was not available for SLE13_CD4
Project description:The gole of this study was to determine whether circulaitng miRNAs could be used as candidate miRNAs of SLE . In this study a miRNA profile was used to determine aberrant expressed circulating miRNAs in patients with system lupus erythematosus (SLE), compared with rheumatoid arthritis (RA) and healthy control (HCs). To further confirm these microarray data, we identify 8 miRNAs (miR-126, miR-21, miR-451, miR-223, miR-16, miR-125a-3p,miR-155,miR-146a) by real-time quantitative PCR in 20 healthy controls and in 55 cases, of whom 30 were diagnosed with SLE and 25 were diagnosed RA. Using microarray-based expression profiling follwed by real-time quantitative polymerase Cycle Reaction (RT-qPCR)validation, we compared the levels of circulating miRNAs in plasma sample from SLE patients, RA patients, and healthy controls
Project description:To screen the differentially expressed lncRNAs, we performed lncRNA profiling using ArrayStar Human LncRNA Microarray in 24 new-onset systemic lupus erythematosus (SLE) patients and 12 age- and sex-matched healthy controls (HCs). For the lncRNA microarray screening, total RNA from plasma was isolated from 12 SLE without nephritis, 12 lupus nephritis (LN) and 12 HCs. Four RNA samples were mixed togther as a pool of sample for microarray analysis. Accordingly, there were each three pooled RNA samples from 12 SLE without nephritis, 12 LN and 12 HCs for microarray analysis. Hierarchical clustering showed the plasma levels of lncRNAs and mRNAs differed significantly between 24 new-onset SLE patients and 12 control subjects. With a fold change ≥ 2 and P ≤ 0.05, we identified 1315 significantly differentially expressed lncRNAs (743 lncRNAs up-regulated and 572 lncRNAs down-regulated) and 1363 differentially expressed mRNAs (745 mRNAs up-regulated and 618 mRNAs down-regulated) in plasma of SLE patients compared with control samples. Overall design: The human LncRNA microarray analysis of the 9 plasma samples from systemic lupus erythematosus patients and healthy controls
Project description:RNA-seq of systemic lupus erythematosus (SLE) whole blood and healthy controls to determine the gene expression changes in these patients. RNA-seq of PAXgene blood from SLE and healthy donors.